Live Analyst Rating Changes 26922 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Naz Rahman
MAXI

Naz Rahman

Maxim Group
Wall Street Analyst
★★★☆☆
#2101
on 13Foresight · ranked by our own returns
51%
Success Rate
+10.5%
Average Return
37 of 73 calls profitable · +25.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 51% of Naz Rahman's ratings turned a profit when each position was held for 1 year — averaging +10.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

115 Buy 16 Hold 0 Sell
Naz's Stock Coverage 26 ratings · 2026-08-23
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SLXN
Silexion Therapeutics
 Aug 19, 2026 HOLD Hold
+15124.6% avg upside
2 analysts
 — -4.6% ·
CLNN
Clene
 Aug 18, 2026 BUY Strong Buy
+654.6% avg upside
11 analysts
$20.00
362.89% Upside
 +5.6% ·
VANI
Vivani Medical
 Aug 18, 2026 BUY Strong Buy
+233.7% avg upside
6 analysts
$4.00
189.95% Upside
 +0.0% ·
ACOG
Alpha Cognition Inc
 Aug 17, 2026 BUY Strong Buy
+84.6% avg upside
5 analysts
$12.00
22.99% Upside
 +0.6% ·
SCNX
Scienture Holdings
 Aug 17, 2026 BUY Strong Buy
+2304.4% avg upside
4 analysts
$1.50
233.59% Upside
 -4.0% ·
CING
Cingulate Inc
 Aug 14, 2026 BUY Strong Buy
+305.4% avg upside
5 analysts
$8.00
44.08% Upside
 +9.0% ·
TLPH
Talphera
 Aug 13, 2026 BUY Buy
+296.0% avg upside
15 analysts
$3.00
152.07% Upside
 +1.7% ·
PALI
Palisade Bio
 Aug 12, 2026 BUY Strong Buy
+1128.1% avg upside
16 analysts
$8.00
281.04% Upside
 +9.2% ·
NVCT
Nuvectis Pharma
 Aug 05, 2026 BUY Strong Buy
+24.5% avg upside
6 analysts
$30.00
27.34% Upside
 +22.3% ·
VRTX
Vertex Pharmaceuticals
 Aug 05, 2026 BUY Strong Buy
-18.8% avg upside
62 analysts
$575.00
5.00% Upside
 +13.9% ·
VKTX
Viking Therapeutics
 Jul 31, 2026 BUY Strong Buy
+111.9% avg upside
31 analysts
$70.00
106.51% Upside
 +4.6% ·
KZIA
Kazia Therapeutics
 Jul 15, 2026 BUY Strong Buy
+89.3% avg upside
8 analysts
$30.00
123.81% Upside
 +7.0% ·
QNRX
Quoin Pharmaceuticals
 Jul 10, 2026 BUY Strong Buy
+449.4% avg upside
7 analysts
$16.00
187.17% Upside
 +14.4% ·
GLMD
Galmed Pharmaceuticals
 Jun 10, 2026 HOLD Buy
+467.6% avg upside
13 analysts
 — +720.0% ·
NXGL
NexGel Inc
 May 19, 2026 BUY Strong Buy
+506.1% avg upside
1 analyst
$2.00
506.15% Upside
 -8.0% ·
AYTU
Aytu BioScience
 May 15, 2026 BUY Strong Buy
+684.8% avg upside
7 analysts
$7.00
195.35% Upside
 +8.7% ·
XTNT
Xtant Medical Holdings
 May 14, 2026 BUY Strong Buy
+1674.9% avg upside
9 analysts
$1.50
361.60% Upside
 -31.9% ·
PCSA
Processa Pharmaceuticals
 Nov 19, 2025 HOLD Strong Buy
+2063.5% avg upside
5 analysts
 — -70.2% ·
NRSN
Neurosense Therapeutics Ltd.
 Aug 07, 2025 HOLD Strong Buy
+2125.6% avg upside
5 analysts
 — -61.5% ·
VRPX
Virpax Pharmaceuticals
 Mar 06, 2025 HOLD Hold
+3999899.9% avg upside
2 analysts
 — · ·
PTPI
Petros Pharmaceuticals
 Dec 18, 2024 BUY Strong Buy
1 analyst
 — · ·
PRFX
PainReform
 Nov 20, 2024 HOLD Buy
+501.7% avg upside
2 analysts
 — -17.1% ·
NMTRQ
9 Meters Biopharma
 May 17, 2023 HOLD Buy
+3234374900.0% avg upside
11 analysts
 — · ·
FRMM
Forum Markets
 Aug 10, 2022 HOLD Strong Buy
+508.3% avg upside
4 analysts
 — · ·
GRDX
GridAI Technologies
 Jan 13, 2022 HOLD Strong Buy
+467.4% avg upside
7 analysts
 — · ·
ADMA
ADMA Biologics
 Aug 12, 2021 BUY Strong Buy
+11.6% avg upside
15 analysts
$6.00
38.96% Downside
 +57.0% ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Naz Rahman — Frequently Asked Questions
How accurate are Naz Rahman's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Naz's ratings were profitable over a one-year hold, with an average return of +10.5% per rating, or +25.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Naz ranked on 13Foresight?
Naz Rahman is currently ranked #2101 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Naz cover?
Naz most recently has ratings on SLXN, CLNN, VANI, ACOG, SCNX, CING, TLPH, PALI, NVCT, VRTX, VKTX, KZIA and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.